Results 191 to 200 of about 29,074 (242)

A novel bispecific antibody targeting OX40L and TNFα for the targeted treatment of rheumatoid arthritis. [PDF]

Antib Ther
Zhang Q, Song S.
europepmc   +1 more source

Ciliary Defects in Inherited Retinal Diseases

Advanced Genetics, Volume 7, Issue 1, March 2026.
The photoreceptor cilium is a specialized sensory organelle essential for vision. This review systematically summarizes the structural and functional defects of the cilium that lead to inherited retinal diseases (IRDs). It highlights key pathogenic genes, elucidates molecular mechanisms of degeneration, and evaluates emerging therapeutic strategies ...
Guizhi Guo, Lin Li, Jun Zhou, Jie Ran
wiley   +1 more source

Case Report: autologous stem cell boost enables hematopoietic recovery after severe cytopenia induced by BCMA-targeted bispecific antibody therapy in multiple myeloma. [PDF]

Front Oncol
Akiyama H, Kakiuchi S, Sakamoto A, Tomigaki N, Fujioka S, Harima I, Niwa R, Takagi I, Kozuki Y, Miyata Y, Yoshihara K, Yoshihara S, Iwata N.   +12 more
europepmc   +1 more source

The European CAR‐T map—Current status and future directions to improve access to CAR T‐cell therapy for hematologic malignancies

HemaSphere, Volume 10, Issue 3, March 2026.
Abstract Despite its great promise, implementation of CAR‐T therapy—a personalized, logistically complex, and expensive treatment—remains challenging, hampering patient access across and within countries. Since 2018, six products have been centrally approved in Europe (i.e., the European Economic Area; EU‐approved) for 15 hematologic malignancy ...
Elise R. A. Pennings, Frederick W. Thielen, Florence Broussais, Julio Delgado, Ulrich Jaeger, Carmen Sanges, Yolanda Cabrerizo, Lutgart Roux‐Opstaele, Caroline Dreuillet, Eglys Gonzalez‐Marcano, Olga Millán, Barbara Huber, Solène Clavreul, Natacha Bolaños, Samantha Nier, Jana Mihályová, Roman Hájek, Michaela Horňáková, Robin Doeswijk, Catherine Thieblemont, Michael Hudecek, Carin A. Uyl‐de Groot, Marie José Kersten   +22 more
wiley   +1 more source

A bridge, not a destination: clarifying the role of polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma. [PDF]

Korean J Intern Med
Yhim HY.
europepmc   +1 more source

Body composition predicts poor outcomes and reveals immunometabolic dysfunction via single‐cell profiling in anti‐BCMA CAR T‐treated myeloma

HemaSphere, Volume 10, Issue 3, March 2026.
Abstract Chimeric antigen receptor (CAR) T‐cell therapy has transformed the treatment of relapsed or refractory multiple myeloma (RRMM), yet outcomes remain heterogenous. The prognostic role of body composition in this context is unknown. We retrospectively analyzed 108 RRMM patients treated with anti‐B‐cell maturation antigen (BCMA) CAR T‐cell therapy.
Thomas C. Wiemers, Michael Rade, Nora Grieb, Maximilian Ferle, Tihomir Dermendzhiev, David Fandrei, Patrick Born, Luise Fischer, Sabine Seiffert, Anja Grahnert, Maik Friedrich, Ronny Baber, Markus Kreuz, Klaus H. Metzeler, Marco Herling, Carmen D. Herling, Madlen Jentzsch, Georg‐Nikolaus Franke, Andreas Boldt, Thomas Neumuth, Urvi A. Shah, Ulrike Köhl, Kristin Reiche, Timm Denecke, Uwe Platzbecker, Vladan Vučinić, Hans‐Jonas Meyer, Maximilian Merz   +27 more
wiley   +1 more source

Bispecific antibodies and CAR T cells targeting a TP53 mutation-associated neoantigen show discordant affinity requirements. [PDF]

J Clin Invest
DiNapoli SR, Wright KM, Mog BJ, Pearlman AH, Nichakawade TD, Marcou N, Hsiue EH, Hwang MS, Douglass J, Liu Q, Watson E, Dal Molin M, Cohen JD, Popoli M, Paul S, Konig MF, Wyhs N, Azurmendi PA, Glavaris S, Ge J, Awosika TO, Liu J, Gabrielson KL, Gabelli SB, Pardoll DM, Bettegowda C, Papadopoulos N, Kinzler KW, Zhou S, Vogelstein B.   +29 more
europepmc   +1 more source

Role of Radiotherapy in the Era of Novel Immune‐Based Treatment Strategies for Multiple Myeloma

Hematological Oncology, Volume 44, Issue 2, March 2026.
ABSTRACT Radiotherapy (RT) constitutes an important treatment modality in multiple myeloma (MM), traditionally used for the management of symptomatic osteolytic and extramedullary lesions. Objectives of RT are symptom alleviation and prevention of complications such as neurological deficits and pathological fractures.
Tom Schlusemann, Evgenii Shumilov, Gabriele Reinartz, David Rene Steike, Sebastian Lohmann, Stefan Gravemeyer, Matthias Stelljes, Georg Lenz, Hans Theodor Eich, Michael Oertel   +9 more
wiley   +1 more source

Negative trial but positive lesson: reframing immunotherapy resistance from one-size-fits-all to precision strategies. [PDF]

BMJ Oncol
Jiang Y, Xu Y, Xia Y.
europepmc   +1 more source

DNA-programmed bispecific peptide assemblies for delivering cytotoxic payload to cells expressing EGFR and MET receptors. [PDF]

RSC Chem Biol
Ghosh P, Dinh H, Seitz O.
europepmc   +1 more source